Elevated expression of miR-210 predicts poor survival of cancer patients: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Wang, Jian ^a   Zhao, Jiqing ^a   Shi, Mengjing ^a   Ding, Yu ^b   Sun, Huiqin ^a   Yuan, Fahuan ^b   Zou, Zhongmin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Xinqiao Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 210; MICRORNA; MIRN210 MICRORNA, HUMAN; TUMOR MARKER;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CANCER; OSTEOSARCOMA; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; SOFT TISSUE SARCOMA; SYSTEMATIC REVIEW; GENETICS; META ANALYSIS; MORTALITY; NEOPLASM; PROGNOSIS; SURVIVAL RATE;

HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84895890496     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089223     Document Type: Article

References (69)

1. Sand M, Gambichler T, Sand D, Skrygan M, Altmeyer P, et al. (2009) MicroRNAs and the skin: tiny players in the body's largest organ. J Dermatol Sci 53: 169-175.
2. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854. (Pubitemid 24014542)
3. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99: 15524-15529. (Pubitemid 35403967)
4. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866. (Pubitemid 44629897)
5. Chan YC, Banerjee J, Choi SY, Sen CK (2012) miR-210: The Master Hypoxamir. Microcirculation 19: 215-223.
6. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, et al. (2007) A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867.
7. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, et al. (2007) MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26: 4442-4452. (Pubitemid 47014466)
8. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, et al. (2008) hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14: 1340-1348. (Pubitemid 351413913)
9. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, et al. (2008) miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 7: 255-264. (Pubitemid 351590433)
10. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675. (Pubitemid 351667616)
11. Duncavage EJ, Goodgame B, Govindin R, Pfeifer JD (2009) Evaluation of microrna markers to predict outcome in low stage lung cancer. Laboratory Investigation 89: 352A-353A.
12. Ho AS, Huang X, Cao H, Koong AC, Le QT (2009) Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients. Journal of Clinical Oncology 27: 4624.
13. Juan D, Alexe G, Antes T, Liu H, Madabhushi A, et al. (2010) Identification of a microRNA panel for clear-cell kidney cancer. Urology 75: 835-841.
14. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, et al. (2010) hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 116: 2148-2158.
15. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, et al. (2010) Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol 3: 109-113.
16. Zhao A, Li G, Peoc'h M, Genin C, Gigante M (2013) Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 94: 115-120.
17. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, et al. (2011) Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE 6: e20980.
18. Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kumpers P, et al. (2011) Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 6: 1540-1546.
19. Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, et al. (2012) High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol 42: 256-263.
20. Qiu S, Lin S, Hu D, Feng Y, Tan Y, et al. (2013) Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med 11: 10.
21. Wotschofsky Z, Busch J, Jung M, Kempkensteffen C, Weikert S, et al. (2013) Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clinica Chimica Acta 416: 5-10.
22. McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, et al. (2013) miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. British Journal of Cancer 108: 1133-1142.
23. Greither T, Wurl P, Grochola L, Bond G, Bache M, et al. (2012) Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer 130: 1230-1235.
24. Zaravinos A, Radojicic J, Lambrou GI, Volanis D, Delakas D, et al. (2012) Expression of miRNAs Involved in Angiogenesis, Tumor Cell Proliferation, Tumor Suppressor Inhibition, Epithelial-Mesenchymal Transition and Activation of Metastasis in Bladder Cancer. The Journal of Urology 188: 615-623.
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Metaanalysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012. (Pubitemid 30214957)
26. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. (Pubitemid 28562978)
27. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
28. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
29. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, et al. (2012) Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A 109: 3024-3029.
30. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, et al. (2010) Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 126: 73-80.
31. Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadle JM (2010) The VHL-dependent regulation of microRNAs in renal cancer. BMC Med 8: 64.
32. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, et al. (2011) MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 10: 507-517.
33. Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, et al. (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 18: 5972-5982.
34. Cai H, Lin L, Cai H, Tang M, Wang Z (2013) Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Medical Oncology 30.
35. Wotschofsky Z, Busch J, Jung M, Kempkensteffen C, Weikert S, et al. (2013) Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clinica Chimica Acta 416: 5-10.
36. Markou A, Yousef GM, Stathopoulos E, Georgoulias V, Lianidou E (2013) Prognostic Significance of Metastasis-Related microRNAs in Early Breast Cancer Patients with a Long Follow-up. Clin Chem.
37. Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, et al. (2011) MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem 286: 420-428.
38. Hong L, Han Y, Zhang H, Zhao Q, Qiao Y (2013) miR-210- a therapeutic target in cancer. Expert Opin Ther Targets 17: 21-28.
39. Yang M, Liu R, Sheng J, Liao J, Wang Y, et al. (2013) Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol Rep 29: 169-176.
40. Zang W, Wang Y, Du Y, Xuan X, Wang T, et al. (2013) Differential expression profiling of microRNAs and their potential involvement in esophageal squamous cell carcinoma. Tumour Biol.
41. Biswas S, Roy S, Banerjee J, Hussain SR, Khanna S, et al. (2010) Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci U S A 107: 6976-6981.
42. Nakada C, Tsukamoto Y, Matsuura K, Nguyen TL, Hijiya N, et al. (2011) Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. The Journal of pathology 224: 280-288.
43. Dirks PB, Rutka JT, Hubbard SL, Mondal S, Hamel PA (1998) The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells. Oncogene 17: 867-876. (Pubitemid 28430209)
44. Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, et al. (1998) E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes & development 12: 2120-2130. (Pubitemid 28348036)
45. Vigo E, Muller H, Prosperini E, Hateboer G, Cartwright P, et al. (1999) CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Molecular and cellular biology 19: 6379-6395. (Pubitemid 29399342)
46. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, et al. (2009) Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 35: 856-867.
47. Mohankumar KM, Xu XQ, Zhu T, Kannan N, Miller LD, et al. (2007) HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. Oncogene 26: 3998-4008. (Pubitemid 46884304)
48. Wang F, Xiong L, Huang X, Zhao T, Wu LY, et al. (2013) miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells. Stem Cell Res 11: 657-667.
49. Chang W, Lee CY, Park JH, Park MS, Maeng LS, et al. (2013) Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1. J Vet Sci 14: 69-76.
50. Grosso S, Doyen J, Parks SK, Bertero T, Paye A, et al. (2013) MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 4: e544.
51. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, et al. (2009) MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8: 2756-2768.
52. Rouault TA, Tong WH (2008) Iron-sulfur cluster biogenesis and human disease. Trends Genet 24: 398-407.
53. Chen Z, Li Y, Zhang H, Huang P, Luthra R (2010) Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 29: 4362-4368.
54. Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, et al. (2011) miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 18: 465-478.
55. Lou YL, Guo F, Liu F, Gao FL, Zhang PQ, et al. (2012) miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. Mol Cell Biochem 370: 45-51.
56. Alaiti MA, Ishikawa M, Masuda H, Simon DI, Jain MK, et al. (2012) Upregulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med 16: 2413-2421.
57. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM (2009) MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer research 69: 1221-1229.
58. Mortensen UH, Lisby M, Rothstein R (2009) Rad52. Curr Biol 19: R676-677.
59. West SC (2003) Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 4: 435-445.
60. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, et al. (2008) MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 283: 15878-15883.
61. Hu SJ, Huang M, Li ZJ, Jia FJ, Ghosh ZM, et al. (2010) MicroRNA-210 as a Novel Therapy for Treatment of Ischemic Heart Disease. Circulation 122: S124-S131.
62. Fasanaro P, Greco S, Lorenzi M, Pescatori M, Brioschi M, et al. (2009) An Integrated Approach for Experimental Target Identification of Hypoxia-induced miR-210. Journal of Biological Chemistry 284: 35134-35143.
63. Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R (2009) Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMB Rep 42: 493-499.
64. Mizuno Y, Tokuzawa Y, Ninomiya Y, Yagi K, Yatsuka-Kanesaki Y, et al. (2009) miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. FEBS letters 583: 2263-2268.
65. Kim HW, Haider HK, Jiang S, Ashraf M (2009) Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 284: 33161-33168.
66. Kopriva SE, Chiasson VL, Mitchell BM, Chatterjee P (2013) TLR3-induced placental miR-210 down-regulates the STAT6/interleukin-4 pathway. PLoS One 8: e67760.
67. Kheirelseid EA, Miller N, Chang KH, Curran C, Hennessey E, et al. (2013) miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int J Colorectal Dis 28: 247-260.
68. Gaca S, Reichert S, Rodel C, Rodel F, Kreuter J (2012) Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: preparation, characterisation, drug release, cytotoxicity and therapeutic effect on colorectal cancer cells. J Microencapsul 29: 685-694.
69. Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, et al. (2012) A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 83: 1113-1119.